Subtypes and Mimics of Sepsis

References

1. • Singer M.
   • Deutschman C.S.
   • Seymour C.W.
   • et al.
   The third international consensus definitions for sepsis and septic shock (Sepsis-3).
   JAMA. 2016; 315: 801-810
   View in Article

   • Google Scholar
2. • Kellum J.A.
   • Kong L.
   • Fink M.P.
   • et al.
   Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the genetic and inflammatory markers of sepsis (GenIMS) study.
   Arch Intern Med. 2007; 167: 1655-1663
   View in Article

   • Google Scholar
3. • Angus D.C.
   • van der Poll T.
   Severe sepsis and septic shock.
   N Engl J Med. 2013; 369: 840-851
   View in Article

   • Google Scholar
4. • Brinkworth J.F.
   • Valizadegan N.
   Sepsis and the evolution of human increased sensitivity to lipopolysaccharide.
   Evol Anthropol. 2021; 30: 141-157
   View in Article

   • Google Scholar
5. • Wassenaar T.M.
   • Zimmermann K.
   Lipopolysaccharides in food, food supplements, and probiotics: should we be worried?.
   Eur J Microbiol Immunol (Bp). 2018; 8: 63-69
   View in Article

   • Google Scholar
6. • Sirivongrangson P.
   • Kulvichit W.
   • Payungporn S.
   • et al.
   Endotoxemia and circulating bacteriome in severe COVID-19 patients.
   Intensive Care Med Exp. 2020; 8: 72
   View in Article

   • Google Scholar
7. • Vincent J.L.
   • Moreno R.
   • Takala J.
   • et al.
   The SOFA (Sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine.
   Intensive Care Med. 1996; 22: 707-710
   View in Article

   • Google Scholar
8. • Sorensen T.I.
   • Nielsen G.G.
   • Andersen P.K.
   • et al.
   Genetic and environmental influences on premature death in adult adoptees.
   N Engl J Med. 1988; 318: 727-732
   View in Article

   • Google Scholar
9. • Rautanen A.
   • Mills T.C.
   • Gordon A.C.
   • et al.
   Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study.
   Lancet Respir Med. 2015; 3: 53-60
   View in Article

   • Google Scholar
10. • Scherag A.
    • Schoneweck F.
    • Kesselmeier M.
    • et al.
    Genetic factors of the disease course after sepsis: a genome-wide study for 28Day mortality.
    EBioMedicine. 2016; 12: 239-246
    View in Article

    • Google Scholar
11. • Kernan K.F.
    • Ghaloul-Gonzalez L.
    • Shakoory B.
    • et al.
    Adults with septic shock and extreme hyperferritinemia exhibit pathogenic immune variation.
    Genes Immun. 2019; 20: 520-526
    View in Article

    • Google Scholar
12. • Yealy D.M.
    • Kellum J.A.
    • Huang D.T.
    • et al.
    A randomized trial of protocol-based care for early septic shock.
    N Engl J Med. 2014; 370: 1683-1693
    View in Article

    • Google Scholar
13. • Crayne C.B.
    • Albeituni S.
    • Nichols K.E.
    • et al.
    The immunology of macrophage activation syndrome.
    Front Immunol. 2019; 10: 119
    View in Article

    • Google Scholar
14. • Otsuka R.
    • Seino K.I.
    Macrophage activation syndrome and COVID-19.
    Inflamm Regen. 2020; 40: 19
    View in Article

    • Google Scholar
15. • Fardet L.
    • Galicier L.
    • Lambotte O.
    • et al.
    Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome.
    Arthritis Rheumatol. 2014; 66: 2613-2620
    View in Article

    • Google Scholar
16. • Debaugnies F.
    • Mahadeb B.
    • Ferster A.
    • et al.
    Performances of the H-score for diagnosis of hemophagocytic lymphohistiocytosis in adult and pediatric patients.
    Am J Clin Pathol. 2016; 145: 862-870
    View in Article

    • Google Scholar
17. • Schulert G.S.
    • Grom A.A.
    Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.
    Annu Rev Med. 2015; 66: 145-159
    View in Article

    • Google Scholar
18. • Ravelli A.
    • Davi S.
    • Minoia F.
    • et al.
    Macrophage activation syndrome.
    Hematol Oncol Clin North Am. 2015; 29: 927-941
    View in Article

    • Google Scholar
19. • Henter J.I.
    • Horne A.
    • Arico M.
    • et al.
    HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.
    Pediatr Blood Cancer. 2007; 48: 124-131
    View in Article

    • Google Scholar
20. • Sullivan K.E.
    • Delaat C.A.
    • Douglas S.D.
    • et al.
    Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives.
    Pediatr Res. 1998; 44: 465-468
    View in Article

    • Google Scholar
21. • Janka G.
    • zur Stadt U.
    Familial and acquired hemophagocytic lymphohistiocytosis.
    Hematology Am Soc Hematol Educ Program. 2005; : 82-88
    View in Article

    • Google Scholar
22. • Henter J.I.
    • Elinder G.
    • Soder O.
    • et al.
    Hypercytokinemia in familial hemophagocytic lymphohistiocytosis.
    Blood. 1991; 78: 2918-2922
    View in Article

    • Google Scholar
23. • Lolachi S.
    • Morin S.
    • Coen M.
    • et al.
    Macrophage activation syndrome as an unusual presentation of paucisymptomatic severe acute respiratory syndrome coronavirus 2 infection: a case report.
    Medicine. 2020; 99: e21570
    View in Article

    • Google Scholar
24. • Kellum J.A.
    • Pike F.
    • Yealy D.M.
    • et al.
    Relationship between alternative resuscitation strategies, host response and injury biomarkers, and outcome in septic shock: analysis of the protocol-based care for early septic shock study.
    Crit Care Med. 2017; 45: 438-445
    View in Article

    • Google Scholar
25. • Billiau A.D.
    • Roskams T.
    • Van Damme-Lombaerts R.
    • et al.
    Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages.
    Blood. 2005; 105: 1648-1651
    View in Article

    • Google Scholar
26. • Hazen M.M.
    • Woodward A.L.
    • Hofmann I.
    • et al.
    Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis.
    Arthritis Rheum. 2008; 58: 567-570
    View in Article

    • Google Scholar
27. • Yanagimachi M.
    • Goto H.
    • Miyamae T.
    • et al.
    Association of IRF5 polymorphisms with susceptibility to hemophagocytic lymphohistiocytosis in children.
    J Clin Immunol. 2011; 31: 946-951
    View in Article

    • Google Scholar
28. • Horby P.W.
    • Pessoa-Amorim G.
    • et al.
    • RECOVERY Collaborative Group
    Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial.
    Lancet. 2021; 397: 1637-1645
    View in Article

    • Google Scholar
29. • Mariette X.
    • Hermine O.
    • Tharaux P.L.
    • et al.
    Effectiveness of tocilizumab in patients hospitalized with COVID-19: a follow-up of the CORIMUNO-TOCI-1 randomized clinical trial.
    JAMA Intern Med. 2021; 181: 1241-1243
    View in Article

    • Google Scholar
30. • Carcillo J.A.
    • Shakoory B.
    • Castillo L.
    Secondary hemophagocytic lymphohistiocytosis, macrophage activation syndrome, and hyperferritinemic sepsis-induced multiple-organ dysfunction syndrome in the pediatric ICU.
    in: Mastropietro C. Valentine K. Pediatric critical care. Springer, Cham2019
    View in Article

    • Google Scholar
31. • Ferrer R.
    • Artigas A.
    • Levy M.M.
    • et al.
    Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain.
    JAMA. 2008; 299: 2294-2303
    View in Article

    • Google Scholar
32. • Kaukonen K.M.
    • Bailey M.
    • Suzuki S.
    • et al.
    Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012.
    JAMA. 2014; 311: 1308-1316
    View in Article

    • Google Scholar
33. • Levy M.M.
    • Rhodes A.
    • Phillips G.S.
    • et al.
    Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study.
    Crit Care Med. 2015; 43: 3-12
    View in Article

    • Google Scholar
34. • Opal S.M.
    • Fisher Jr., C.J.
    • Dhainaut J.F.
    • et al.
    Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
    Crit Care Med. 1997; 25: 1115-1124
    View in Article

    • Google Scholar
35. • Shakoory B.
    • Carcillo J.A.
    • Chatham W.W.
    • et al.
    Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial.
    Crit Care Med. 2016; 44: 275-281
    View in Article

    • Google Scholar
36. • Carcillo J.A.
    • Halstead E.S.
    • Hall M.W.
    • et al.
    Three hypothetical inflammation pathobiology phenotypes and pediatric sepsis-induced multiple organ failure outcome.
    Pediatr Crit Care Med. 2017; 18: 513-523
    View in Article

    • Google Scholar
37. • Kyriazopoulou E.
    • Leventogiannis K.
    • Norrby-Teglund A.
    • et al.
    Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis.
    BMC Med. 2017; 15: 172
    View in Article

    • Google Scholar
38. • Tarr P.I.
    • Gordon C.A.
    • Chandler W.L.
    Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.
    Lancet. 2005; 365: 1073-1086
    View in Article

    • Google Scholar
39. • Noris M.
    • Remuzzi G.
    Atypical hemolytic-uremic syndrome.
    N Engl J Med. 2009; 361: 1676-1687
    View in Article

    • Google Scholar
40. • Kavanagh D.
    • Goodship T.
    Genetics and complement in atypical HUS.
    Pediatr Nephrol. 2010; 25: 2431-2442
    View in Article

    • Google Scholar
41. • Osborne A.J.
    • Breno M.
    • Borsa N.G.
    • et al.
    Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 Glomerulopathy.
    J Immunol. 2018; 200: 2464-2478
    View in Article

    • Google Scholar
42. • Noris M.
    • Mescia F.
    • Remuzzi G.
    STEC-HUS, atypical HUS and TTP are all diseases of complement activation.
    Nat Rev Nephrol. 2012; 8: 622-633
    View in Article

    • Google Scholar
43. • Zimmerhackl L.B.
    • Besbas N.
    • Jungraithmayr T.
    • et al.
    Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome.
    Semin Thromb Hemost. 2006; 32: 113-120
    View in Article

    • Google Scholar
44. • Taveira da Silva A.M.
    • Kaulbach H.C.
    • Chuidian F.S.
    • et al.
    Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin.
    N Engl J Med. 1993; 328: 1457-1460
    View in Article

    • Google Scholar
45. • Beeson P.B.
    Development of tolerance to typhoid bacterial pyrogen and its abolition by reticulo-endothelial blockade.
    Proc Soc Exp Biol Med. 1946; 61: 248-250
    View in Article

    • Google Scholar
46. • Fine D.P.
    Activation of the classic and alternate complement pathways by endotoxin.
    J Immunol. 1974; 112: 763-769
    View in Article

    • Google Scholar
47. • Chelakkot C.
    • Ghim J.
    • Ryu S.H.
    Mechanisms regulating intestinal barrier integrity and its pathological implications.
    Exp Mol Med. 2018; 50: 1-9
    View in Article

    • Google Scholar
48. • Hurley J.C.
    Towards clinical applications of anti-endotoxin antibodies; a re-appraisal of the disconnect.
    Toxins (Basel). 2013; 5: 2589-2620
    View in Article

    • Google Scholar
49. • Behre G.
    • Schedel I.
    • Nentwig B.
    • et al.
    Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins.
    Antimicrob Agents Chemother. 1992; 36: 2139-2146
    View in Article

    • Google Scholar
50. • Wortel C.H.
    • von der Mohlen M.A.
    • van Deventer S.J.
    • et al.
    Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels.
    J Infect Dis. 1992; 166: 1367-1374
    View in Article

    • Google Scholar
51. • Opal S.M.
    • Laterre P.F.
    • Francois B.
    • et al.
    Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
    JAMA. 2013; 309: 1154-1162
    View in Article

    • Google Scholar
52. • Shimizu T.
    • Miyake T.
    • Tani M.
    History and current status of polymyxin B-immobilized fiber column for treatment of severe sepsis and septic shock.
    Ann Gastroenterol Surg. 2017; 1: 105-113
    View in Article

    • Google Scholar
53. • Fujimori K.
    • Tarasawa K.
    • Fushimi K.
    Effects of polymyxin B hemoperfusion on septic shock patients requiring noradrenaline: analysis of a nationwide administrative database in Japan.
    Blood Purif. 2021; 50: 560-565
    View in Article

    • Google Scholar
54. • Fujimori K.
    • Tarasawa K.
    • Fushimi K.
    Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study.
    Ann Intensive Care. 2021; 11: 141
    View in Article

    • Google Scholar
55. • Payen D.M.
    • Guilhot J.
    • Launey Y.
    • et al.
    Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial.
    Intensive Care Med. 2015; 41: 975-984
    View in Article

    • Google Scholar
56. • Dellinger R.P.
    • Bagshaw S.M.
    • Antonelli M.
    • et al.
    Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial.
    JAMA. 2018; 320: 1455-1463
    View in Article

    • Google Scholar
57. • Carcillo J.A.
    • Kellum J.A.
    Is there a role for plasmapheresis/plasma exchange therapy in septic shock, MODS, and thrombocytopenia-associated multiple organ failure? We still do not know--but perhaps we are closer.
    Intensive Care Med. 2002; 28: 1373-1375
    View in Article

    • Google Scholar
58. • Ikeda T.
    • Ikeda K.
    • Suda S.
    • et al.
    Usefulness of the endotoxin activity assay as a biomarker to assess the severity of endotoxemia in critically ill patients.
    Innate Immun. 2014; 20: 881-887
    View in Article

    • Google Scholar
59. • Marshall J.C.
    • Foster D.
    • Vincent J.L.
    • et al.
    Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study.
    J Infect Dis. 2004; 190: 527-534
    View in Article

    • Google Scholar
60. • Klein D.J.
    • Foster D.
    • Schorr C.A.
    • et al.
    The EUPHRATES trial (Evaluating the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial.
    Trials. 2014; 15: 218
    View in Article

    • Google Scholar
61. • Seymour C.W.
    • Kennedy J.N.
    • Wang S.
    • et al.
    Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis.
    JAMA. 2019; 321: 2003-2017
    View in Article

    • Google Scholar